Dynamics of human protein kinase Aurora A linked to drug selectivity
Abstract
Protein kinases are major drug targets, but the development of highly-selective inhibitors has been challenging due to the similarity of their active sites. The observation of distinct structural states of the fully-conserved Asp-Phe-Gly (DFG) loop has put the concept of conformational selection for the DFG-state at the center of kinase drug discovery. Recently, it was shown that Gleevec selectivity for the Tyr-kinases Abl was instead rooted in conformational changes after drug binding. Here, we investigate whether protein dynamics after binding is a more general paradigm for drug selectivity by characterizing the binding of several approved drugs to the Ser/Thr-kinase Aurora A. Using a combination of biophysical techniques, we propose a universal drug-binding mechanism, that rationalizes selectivity, affinity and long on-target residence time for kinase inhibitors. These new concepts, where protein dynamics in the drug-bound state plays the crucial role, can be applied to inhibitor design of targets outside the kinome.
Data availability
Diffraction data have been deposited in PDB under the accession codes 6CPE, 6CPF, 6CPG.
-
Structure of apo, dephosphorylated Aurora A (122-403) in an active conformationPublicly available at RCSB Protein Data Bank (accession no: 6CPE).
-
Structure of dephosphorylated Aurora A (122-403) bound to AMPPCP in an active conformationPublicly available at RCSB Protein Data Bank (accession no: 6CPF).
-
Structure of dephosphorylated Aurora A (122-403) in complex with inhibiting monobody and AT9283 in an inactive conformationPublicly available at RCSB Protein Data Bank (accession no: 6CPG).
-
Structure of dephosphorylated Aurora A (122-403) bound to AMPPCPPublicly available at RCSB Protein Data Bank (accession no: 4C3R).
-
CRYSTAL STRUCTURE OF AURORA-2, AN ONCOGENIC SERINE-THREONINE KINASEPublicly available at RCSB Protein Data Bank (accession no: 1MUO).
-
Structure of Human Aurora-A 122-403 phosphorylated on Thr287, Thr288Publicly available at RCSB Protein Data Bank (accession no: 1OL7).
-
Structure determination of Aurora Kinase in complex with inhibitorPublicly available at RCSB Protein Data Bank (accession no: 2W1G).
-
Structure of Aurora-2 in complex with PHA-739358Publicly available at RCSB Protein Data Bank (accession no: 2J50).
Article and author information
Author details
Funding
Howard Hughes Medical Institute
- Dorothee Kern
National Institutes of Health (GM100966-01)
- Dorothee Kern
U.S. Department of Energy (DE-FG02-05ER15699)
- Dorothee Kern
Damon Runyon Cancer Research Foundation (DRG-2114-12)
- Renee Otten
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Philip A Cole, Harvard Medical School, United States
Publication history
- Received: March 14, 2018
- Accepted: June 12, 2018
- Accepted Manuscript published: June 14, 2018 (version 1)
- Version of Record published: July 20, 2018 (version 2)
Copyright
© 2018, Pitsawong et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 4,026
- Page views
-
- 726
- Downloads
-
- 27
- Citations
Article citation count generated by polling the highest count across the following sources: Crossref, Scopus, PubMed Central.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Cancer Biology
- Cell Biology
Pancreatic ductal adenocarcinoma (PDAC) continues to show no improvement in survival rates. One aspect of PDAC is elevated ATP levels, pointing to the purinergic axis as a potential attractive therapeutic target. Mediated in part by highly druggable extracellular proteins, this axis plays essential roles in fibrosis, inflammation response and immune function. Analysing the main members of the PDAC extracellular purinome using publicly available databases discerned which members may impact patient survival. P2RY2 presents as the purinergic gene with the strongest association with hypoxia, the highest cancer cell-specific expression and the strongest impact on overall survival. Invasion assays using a 3D spheroid model revealed P2Y2 to be critical in facilitating invasion driven by extracellular ATP. Using genetic modification and pharmacological strategies we demonstrate mechanistically that this ATP-driven invasion requires direct protein-protein interactions between P2Y2 and αV integrins. DNA-PAINT super-resolution fluorescence microscopy reveals that P2Y2 regulates the amount and distribution of integrin αV in the plasma membrane. Moreover, receptor-integrin interactions were required for effective downstream signalling, leading to cancer cell invasion. This work elucidates a novel GPCR-integrin interaction in cancer invasion, highlighting its potential for therapeutic targeting.
-
- Cancer Biology
Osteosarcoma (OS) is the common primary bone cancer that affects mostly children and young adults. To augment the standard-of-care chemotherapy, we examined the possibility of protein-based therapy using mesenchymal stem cells (MSCs)-derived proteomes and OS-elevated proteins. While a conditioned medium (CM), collected from MSCs, did not present tumor-suppressing ability, the activation of PKA converted MSCs into induced tumor-suppressing cells (iTSCs). In a mouse model, the direct and hydrogel-assisted administration of CM inhibited tumor-induced bone destruction, and its effect was additive with cisplatin. CM was enriched with proteins such as calreticulin, which acted as an extracellular tumor suppressor by interacting with CD47. Notably, the level of CALR transcripts was elevated in OS tissues, together with other tumor-suppressing proteins, including histone H4, and PCOLCE. PCOLCE acted as an extracellular tumor-suppressing protein by interacting with amyloid precursor protein, a prognostic OS marker with poor survival. The results supported the possibility of employing a paradoxical strategy of utilizing OS transcriptomes for the treatment of OS.